Shionogi & Co., Ltd. (TYO:4507)
Japan · Delayed Price · Currency is JPY 2,443.00
-8.00 (-0.33%)
Oct 24, 2025, 3:30 PM JST
Shionogi & Revenue
Shionogi & had revenue of 99.78B JPY in the quarter ending June 30, 2025, with 2.25% growth. This brings the company's revenue in the last twelve months to 440.50B, up 4.05% year-over-year. In the fiscal year ending March 31, 2025, Shionogi & had annual revenue of 438.27B with 0.73% growth.
Revenue (ttm)
440.50B
Revenue Growth
+4.05%
P/S Ratio
4.72
Revenue / Employee
88.90M
Employees
4,955
Market Cap
2.08T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
| Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
| Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
| Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
| Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.48T |
| Otsuka Holdings | 2.40T |
| Astellas Pharma | 1.94T |
| Daiichi Sankyo Company | 1.92T |
| Chugai Pharmaceutical | 1.20T |
| Terumo | 1.04T |
| Olympus | 969.02B |
| HOYA Corporation | 876.09B |
Shionogi & News
- 3 months ago - Shionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Shionogi & Co. reports Q1 results - Seeking Alpha
- 5 months ago - Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B - Seeking Alpha
- 6 months ago - Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B - Seeking Alpha
- 9 months ago - Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder - Benzinga
- 9 months ago - Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 9 months ago - Shionogi targets JPY550B revenue through QOL focus and global expansion - Seeking Alpha